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Introduction {#sec005}
============

Menopausal hot flushes (MHF) refer to spontaneous but transient erythema and warm or burning sensation on the face and neck which affects 60--70% women during the menopausal period \[[@pone.0222383.ref001]\]. It has become the primary reason for females to seek medical help \[[@pone.0222383.ref002]\]. Despite the observation that symptoms will resolve spontaneously and halt ultimately even without any treatments, the average persistent duration of MHF is 2.5 years \[[@pone.0222383.ref003]\] and in approximately 10--15% cases it could last up to decades or even longer after menopause \[[@pone.0222383.ref004]\]. Therefore, MHF is commonly considered as a negative domain of the quality of life (QoL) in middle-aged women which can vitally impact on concentration and emotional abilities during daily activities \[[@pone.0222383.ref005]\]. Although the precise mechanism of MHF is not known, a sudden reduction in estrogen level, changes in neurotransmitters (serotonin and norepinephrine), calcitonin gene-related peptide (CGRP) and neurokinin-B are among those considered as players in the pathomechanism of MHF \[[@pone.0222383.ref006]\].

Current therapies including menopausal hormone therapy (or hormone replacement therapy, HRT) and paroxetine ([selective serotonin reuptake inhibitors](https://www.drugs.com/drug-class/ssri-antidepressants.html)) are the recommended therapies for MHF by the North American Menopause Society (NAMS) \[[@pone.0222383.ref007], [@pone.0222383.ref008]\]. Although these therapies are efficacious, they are not without adverse events (AEs), such as nausea, dizziness and dry mouth. Additionally, HRT is contraindicated with hormone-dependent diseases (e.g. breast cancer) and past discontinuation of HRT may contribute to a rebound in hot flushes \[[@pone.0222383.ref009]--[@pone.0222383.ref011]\].

Therefore, a tremendous effort has been invested to search for natural products. The Study of Women's Health Across the Nation (United States), a longitudinal six-year prospective cohort study, reported that approximately 80% of 3302 investigated females during menopausal transition have used complementary and alternative medicine (CAM) during the six-year investigation period \[[@pone.0222383.ref012]\]. Among these CAM, Chinese herbal medicine (CHM) is a popularly prescribed therapy for MHF management in real-life clinical practice and widely studied in clinical trials. However, to date, they have not been systematically reviewed. This study aimed to conduct a systematic review which offers a comprehensive evaluation of the therapeutic effects and safety of CHM for MHF and identify the most commonly used CHM formulae and individual herbs for MHF.

Methods {#sec006}
=======

This systematic review was conducted following the requirements of the Cochrane Handbook \[[@pone.0222383.ref013]\] and the PRISMA checklist ([S1 PRISMA checklist](#pone.0222383.s001){ref-type="supplementary-material"}) \[[@pone.0222383.ref014]\].

Data sources and search strategies {#sec007}
----------------------------------

Five English databases (Cochrane Library, PubMed, EMBASE, CINAHL and AMED) and two Chinese databases (CNKI and sinoMed) were searched for studies published in English and Chinese from their respective inceptions to May 2018, and updated in February 2019, by using MeSH terms of MHF and CHM and their synonyms as keywords. The results were exported into and managed by EndNote library. The reference lists of relevant trials and reviews were screened for additional studies. Sample search strategies are provided in [S1 Table](#pone.0222383.s002){ref-type="supplementary-material"}.

Study screening and selection criteria {#sec008}
--------------------------------------

Articles retrieved for evaluation were assessed by two independent reviewers. One reviewer performed the screening of the title and abstract and two independent reviewers screened the full-text of potential records for eligibility. The disagreement was discussed between the two reviewers. If an agreement could not be reached between the two reviewers, the discrepancies were discussed with the third party. All the searched articles were screened and evaluated according to inclusion and exclusion criteria. The articles were considered for inclusion if they 1) were randomized controlled trials (RCTs), 2) recruited female participants who were experiencing MHF during or after natural or artificial menopause transition, 3) contained CHM formulae in any forms (decoction or capsule) as treatment, and 4) included conventional treatment (hormone or western medication), placebo or no treatment as a control intervention.

Articles with ineligible participant: 1) hot flushes related to breast cancer or drug-induced hot flushes or 2) no diagnostic criteria for MHF were excluded. Articles were excluded if they used any of following CHM interventions: 1) single herbs, chemical compounds extracted from herbs, and supplements; or 2) individualized CHM formulae for participants (i.e. modification of formula according to symptoms); or 3) external application of herbal formulae. Articles with control group other than placebo, conventional treatment (hormone therapy or western medication) or no treatment were not considered for inclusion in this review. Studies involving inappropriate comparison leading to the effects of CHM formulae could not be determined were also excluded. Co-intervention was not considered for inclusion in this review.

Data extraction {#sec009}
---------------

Data were extracted from included studies by two independent reviewers. The data extracted to a predesigned data collection form included details about the study design, setting, sample size, participants' age, diagnosis, interventions, duration and outcome measures.

In this review, the primary outcome measures were the subjective feelings of MHF including effectiveness rate, frequency, severity and score (i.e. an MHF score was calculated by multiplying the number of MHF severity score by the frequency of daily MHF) of MHF symptom, the Kupperman index (KI) score (limited to the total score and vasomotor domain score) and the QoL (limited to the total score and vasomotor domain score). The secondary outcome measures were the objective measurements of MHF including menopause-related hormone levels (i.e. follicle-stimulating hormone \[FSH\], luteinizing hormone \[LH\] and estradiol \[E~2~\]) and peripheral blood flow. Included studies containing these data were considered for further data analysis. The most commonly studied formulae, herb pairs and herbs in the included studies were descriptively summarized. The compatibility of herb pairs was networked using Gephi (<https://gephi.org/>).

Data synthesis and analysis {#sec010}
---------------------------

The quality of included RCTs was assessed against the risk of bias (e.g. selection, performance, attrition, detection and reporting biases) according to the Cochrane Handbook \[[@pone.0222383.ref013]\] independently by two reviewers. The disagreement was discussed between the two reviewers or with a third party.

The extracted quantitative data from published studies were analyzed using RevMan 5.3 \[[@pone.0222383.ref015]\]. Dichotomous data (i.e. effectiveness rate) were weighted by odds ratio (OR). Continuous data of the hormone levels were weighted by the mean difference (MD) with 95% confidence intervals (CI). The standardized mean difference (SMD) was utilized instead of MD when different scales were used in more than one study for the same outcome measures including MHF relief (frequency, severity and score), KI score and QoL. Heterogeneity was assessed statistically using I^2^. To minimize the potential heterogeneity, random effects were applied where I^2^ was over 50% \[[@pone.0222383.ref013]\]. The descriptive synthesis was also used to aid in data presentation when appropriate. Sensitivity analysis was also considered where applicable. Rosenthal Failsafe-N were calculated using Meta-Essentials 1.4 version \[[@pone.0222383.ref016]\] for publication bias where more than one study was included in a outcome measure \[[@pone.0222383.ref017]\].

Results {#sec011}
=======

A total of 1630 papers were obtained from the database search and 22 articles were found through manual search. Nineteen articles met inclusion criteria and were included in this review \[[@pone.0222383.ref018]--[@pone.0222383.ref036]\] and 16 were included in the meta-analysis \[[@pone.0222383.ref018]--[@pone.0222383.ref026], [@pone.0222383.ref028], [@pone.0222383.ref030], [@pone.0222383.ref031], [@pone.0222383.ref033]--[@pone.0222383.ref036]\]. Three were not included in the meta analysis due to lack of data \[[@pone.0222383.ref027], [@pone.0222383.ref029], [@pone.0222383.ref032]\]. The selection process for included studies with exclusion details is shown in [Fig 1](#pone.0222383.g001){ref-type="fig"}.

![PRISMA flow chart on study selection procedures of Chinese herbal medicines for the management of menopausal hot flushes.](pone.0222383.g001){#pone.0222383.g001}

Description of studies {#sec012}
----------------------

All of the 19 included studies are RCTs which recruited 2469 participants (1365 in the CHM groups, 1024 in the control groups, and one study did not specify the group allocation of 80 participants in the recruitment stage \[[@pone.0222383.ref023]\]) and analyzed 2309 participants at the end of treatment. These trials were conducted worldwide including 11 in mainland China \[[@pone.0222383.ref018]--[@pone.0222383.ref024], [@pone.0222383.ref026], [@pone.0222383.ref028], [@pone.0222383.ref034], [@pone.0222383.ref036]\], two in Hong Kong \[[@pone.0222383.ref030], [@pone.0222383.ref035]\], two in Australia \[[@pone.0222383.ref027], [@pone.0222383.ref033]\], two in America \[[@pone.0222383.ref029], [@pone.0222383.ref032]\], one in Japan \[[@pone.0222383.ref025]\] and one in Switzerland \[[@pone.0222383.ref031]\]. Thirteen of them were published in English \[[@pone.0222383.ref018], [@pone.0222383.ref024], [@pone.0222383.ref025], [@pone.0222383.ref027]--[@pone.0222383.ref036]\] and six published in Chinese \[[@pone.0222383.ref019]--[@pone.0222383.ref023], [@pone.0222383.ref026]\].

All the involved studies involved female participants only. They were diagnosed with MHF: 12 studies applied laboratory tests of hormone level to determine the menopause transition \[[@pone.0222383.ref018], [@pone.0222383.ref019], [@pone.0222383.ref021], [@pone.0222383.ref023]--[@pone.0222383.ref025], [@pone.0222383.ref027], [@pone.0222383.ref028], [@pone.0222383.ref030]--[@pone.0222383.ref033]\]; hot flushes were all diagnosed by participants' subjective feeling. The duration of MHF intervention varied from 4 weeks to 12 months. Regarding the types of herbal medicine, seven RCTs used CHM in granule \[[@pone.0222383.ref025], [@pone.0222383.ref027]--[@pone.0222383.ref029], [@pone.0222383.ref034]--[@pone.0222383.ref036]\], five in capsule \[[@pone.0222383.ref019], [@pone.0222383.ref023], [@pone.0222383.ref024], [@pone.0222383.ref030], [@pone.0222383.ref031]\], three in decoction \[[@pone.0222383.ref020], [@pone.0222383.ref022], [@pone.0222383.ref026]\], two in tablet \[[@pone.0222383.ref032], [@pone.0222383.ref033]\] and two in honey pill form \[[@pone.0222383.ref018], [@pone.0222383.ref021]\]. The number of ingredients of CHM formulae ranged from 2 to 31 herbs. Among the 19 studies, nine of them compared CHM with HRT \[[@pone.0222383.ref018]--[@pone.0222383.ref026]\] and ten compared CHM with placebo \[[@pone.0222383.ref027]--[@pone.0222383.ref036]\]. No studies comparing CHM with no treatment were identified. The characteristics of included studies are summarized in [Table 1](#pone.0222383.t001){ref-type="table"} and details of ingredients of CHM formulae are provided in [S2 Table](#pone.0222383.s003){ref-type="supplementary-material"}.

10.1371/journal.pone.0222383.t001

###### Characteristics of included studies of Chinese herbal formulae on menopausal hot flushes.

![](pone.0222383.t001){#pone.0222383.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID                                                    Setting                                         Sample size/ EoT                                                                                                                                                                                 Diagnosis of menopause transition                                                                                                                                                            Diagnosis for MHF                                         Duration    Interventions                                                                                      Outcome measures                                                                                                                                                                                                                       
  ----------------------------------------------------------- ----------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- ----------- -------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CHM vs HRT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  **Azizi et al. 2011 \[[@pone.0222383.ref018]\]**            Hospital of university                          48 (T: 24, C: 24)/37 (T~1~: 22, C: 15)                                                                                                                                                           FSH 10 IU/L or menstrual irregularities                                                                                                                                                      ≥ 3 symptoms in KI index                                  2 months    Kun Bao Wan honey pill, 1 sachet, twice/day                                                        Steady conjugated estrogen 0.625 mg/day + medroxy progesterone acetate 2 mg/day or conjugated estrogen 0.625 mg/day for 28 days + medroxy progesterone acetate (NS form), 4 mg/day in the last 12 days repeated after 7 days of rest   KI scale (overall), FSH, E~2~, number of symptoms before and after treatment, AE

  **Chen 2014 \[[@pone.0222383.ref019]\]**                    Hospital                                        100/100 (T: 50, C: 50)                                                                                                                                                                           Amenorrhea ≥ 3 months, FSH ≥ 20 IU/L, E~2~ ≤ 30 pg/mL                                                                                                                                        ≥ 3 MHF per day                                           3 months    Kun Tai capsule, 4 capsules, 3 times/day                                                           E~2~ valerate tablet, 0.5 mg, once/day                                                                                                                                                                                                 Modified KI scale, MHF effectiveness rate, hormone (E~2~), MI

  **Fu et al. 2015a \[[@pone.0222383.ref020]\]**              Health centre                                   98/98 (T: 50, C: 48)                                                                                                                                                                             According to textbook 'Obstetrics and Gynecology' 7th edition                                                                                                                                KI index                                                  1 month     Chinese herbal formula, 100ml, twice/day                                                           Nilestriol tablet, 2 mg/week                                                                                                                                                                                                           Overall effectiveness rate, modified KI scale, AE

  **Li et al.**\                                              Clinic of hospital                              160/160 (T: 80, C: 80)                                                                                                                                                                           According to textbook 'Obstetrics and Gynecology' 7th edition, FSH ≥ 40 IU/L, E~2~ ≤ 30 pg/mL                                                                                                Total KI index ≥ 10, one symptom score ≥ 2, symptomatic   3 months    Ding Kun Dan, 1 pill, twice/day                                                                    Tibolone tablet, 2.5 mg/day                                                                                                                                                                                                            Effectiveness rate (modified KI scale), prevalence of osteoporosis, MHF and sweating, hormone (FSH, LH, E~2~), liver and kidney function, AE
  **2018 \[[@pone.0222383.ref021]\]**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  **Liu 2008 \[[@pone.0222383.ref022]\]**                     Hospital                                        64/64 (T: 32, C: 32)                                                                                                                                                                             According to textbook 'Obstetrics and Gynecology' 5th edition                                                                                                                                Symptomatic                                               4 weeks     Modified Dan Zhi Xiao Yao San, 1 bag, once/day                                                     Premarin tablet (conjugated estrogens 0.3 mg, three times/day) for 28 days + medroxyprogesterone acetate (NS form) 10 mg/day for 5 days                                                                                                Effectiveness rate of symptoms, AE

  **Luan et al. 2004 \[[@pone.0222383.ref023]\]**             Hospital                                        80/66 (T: 33, C: 33)                                                                                                                                                                             Natural amenorrhea ≥ 3 months, FSH ≥ 40 mIU/mL, E~2~ ≤ 30 μg/L                                                                                                                               ≥ 3 MHF and sweating per day                              3 months    Kun Tai capsule, N/A                                                                               E~2~ valerate tablet, 0.5 mg                                                                                                                                                                                                           Modified KI scale, hormone (FSH, E~2~), biochemical indicators, AE

  **Sun et al. 2018 \[[@pone.0222383.ref024]\]**              Clinical centers                                390 (T: 196, C: 194)/318 (T: 159, C: 159)                                                                                                                                                        Amenorrhea for 3 months to 3 years or hysterectomy within 3 years, E~2~ \< 30 ng/L, FSH \> 40 IU/L                                                                                           Symptomatic                                               12 months   He Yan Kun Tai Capsule, 4 capsules, twice/day                                                      Conjugated estrogen tablets (average daily dose 0.45 mg, alternate 0.6 mg and 0.3 mg), for patients without hysterectomy + medroxyprogesterone acetate tablets (2 mg/day)                                                              KI scale, hot flush score, insomnia score, MENQOL, AE

  **Ushiroyama et al. 2005 \[[@pone.0222383.ref025]\]**       College                                         140 (T: 70, C: 70)/131 (T: 67, C: 64)                                                                                                                                                            Amenorrhea ≥ 6 months, FSH \> 30 mIU/mL, LH \> 20 mIU/mL, E~2~ \< 20 pg/mL                                                                                                                   With climacteric complaints                               1 month     Gui Zhi Fu Ling Wan granule, 7.5 g/day                                                             Oral HRT consisting of combined conjugated equine estrogen (Premarin tablet, 0.625 mg/day) and medroxy progesterone acetate (Provera tablet, 2.5 mg/day)                                                                               Blood flow (under the jaw, fingertip, toe tip)

  **Zhou & Li 2016 \[[@pone.0222383.ref026]\]**               Hospital                                        66/66 (T: 32, C: 34)                                                                                                                                                                             According to textbook 'Obstetrics and Gynecology' 7th edition                                                                                                                                KI index                                                  1 month     Chinese herbal formula, 100 mL, twice/day                                                          E~2~ valerate tablet, 1 mg, once/day                                                                                                                                                                                                   Effectiveness rate, modified KI scale, effectiveness rate of symptom improvement (overall), AE

  CHM vs placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  **Davis et al. 2001 \[[@pone.0222383.ref027]\]**            Medical center                                  78 (T: 42, C: 36)/55 (T: 28, C: 27)                                                                                                                                                              Postmenopausal (\>12 months amenorrhea, FSH \> 25 IU/L)                                                                                                                                      ≥ 14 MHF or night sweats per week                         12 weeks    CHM formula granule, 1 sachet, twice/day                                                           Placebo, 1 sachet, twice/day                                                                                                                                                                                                           Changing in frequency of hot flushes and night sweats (daily diary), MENQOL, total urinary diadzein and genistein excretion, AE

  **Fu et al. 2015b \[[@pone.0222383.ref028]\]**              Hospital of university                          389 (T~1.1~: 49, T~1.2~: 50, T~1.3~: 51 C~1~: 49; T~2.1~: 48, T~2.2~: 47, T~2.3~: 47, C~2~: 48)/383 (T~1.1~: 45, T~1.2~: 50, T~1.3~: 50 C~1~:48; T~2.1~: 47, T~2.2~: 47, T~2.3~: 47, C~2~: 48)   1\. Perimenopausal subgroup (irregular menstruation ≥ 3 months or amenorrhea \< 12 months, FSH ≥ 10 IU/L) or early postmenopausal subgroup (amenorrhea between 1--5 years, FSH ≥ 20 IU/L)\   ≥ 14 times each week in the past 4 weeks                  8 weeks     1\) Dan Zhi Qing E formula granule (modified Qing E Tang, DZQE), 4.5 g\                            Placebo, NS                                                                                                                                                                                                                            MENQOL (total, vasomotor, psychosocial, physical), hormone level (FSH, E~2~, testosterone), blood lipid profile, AE
                                                                                                                                                                                                                                                                                                               2. Diagnostic criteria for menopausal symptom                                                                                                                                                                                                                      2) Er Zhi formula (EZ) granule, 2 g\                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  3) Combined DZQE and EZ, 6.5 g, unspecified frequency                                                                                                                                                                                                                                                                                     

  **Grady et al. 2009 \[[@pone.0222383.ref029]\]**            University                                      217/217 (T~1~: 71, T~2~: 75, C: 71)                                                                                                                                                              Postmenopausal                                                                                                                                                                               ≥ 7/day moderate to severe hot flushes or 50/ week        12 weeks    MF 101 granule, 1) 5 g/day; 2) 10 g/day, one dose packed powder, twice/day                         Placebo, one dose packed powder, twice/day                                                                                                                                                                                             Frequency and severity of hot flushes (diary), MENQOL, Female Sexual Function Index, blood pressure, heart rate, breast and pelvic physical examination, endometrial double wall thickness, AE

  **Haines et al. 2008 \[[@pone.0222383.ref030]\]**           Clinic of hospital                              100 (T: 50, C: 50)/84 (T: 45, C: 39)                                                                                                                                                             FSH \> 18 IU/L, LH \> 12.6 IU/L, E~2~ \< 361 pmol/L; women with amenorrhea for ≥ 12 months.                                                                                                  Symptomatic                                               24 weeks    Dang Gui Bu Xue Tang capsule, 6 capsules (3g)/day                                                  Placebo, 6 capsules/day                                                                                                                                                                                                                Frequency of hot flushes with different severity, night sweats (daily diary), MENQOL (vasomotor, psychosocial, physical, sexual), AE

  **Nedeljkovic et al. 2014 \[[@pone.0222383.ref031]\]**      Hospital of university                          20 (T: 10, C: 10)/19 (T: 10, C: 9)                                                                                                                                                               Amenorrhea ≥ 12 months or had hysterectomy, initial score of ≥ 20 points on the MRS II, FSH \> 30 IU/L                                                                                       MHF ≥ 1 year, ≥ 20 MHF per week                           12 weeks    Zhi Mu 14 capsule, 3 capsules, twice/day                                                           Placebo, 3 capsules, twice/day                                                                                                                                                                                                         Severity and frequency of hot flushes, MRS II score (total, psychological, somatic, urogenital), AE

  **Plotnikoff et al. 2011 \[[@pone.0222383.ref032]\]**       University                                      178/178 (T~1~: 57, T~2~: 62, C: 59)                                                                                                                                                              Amenorrhea ≥ 12 months; previous hysterectomy without oophorectomy, FSH ≥ 40 mIU/mL, E~2~ ≤ 20 pg/mL; 2 months past surgery for hysterectomy with oophorectomy.                              Mayo Hot Flash score ≥ 28/week                            3 months    Gui Zhi Fu Ling Wan tablet, 1) low dose 7.5 g/day; 2) high dose 12.5 g/day, 5 tablets, twice/day   Placebo, 5 tablets, twice/day                                                                                                                                                                                                          Frequency and severity of hot flushes (daily diary), GCL, Sleep quality (PSQI), liver function tests, complete blood counts, hormone, AE

  **van der Sluijs et al. 2009 \[[@pone.0222383.ref033]\]**   Clinical research center, clinics, university   92/92 (T: 46, C: 46)                                                                                                                                                                             Amenorrhea ≥ 12 months, FSH ≥ 40 mIU/mL, E~2~ ≤ 80 pg/mL                                                                                                                                     Average 5 vasomotor symptoms per day (\~ 35/ week)        16 weeks    modified Er Xian Tang + Zhi Bai Di Huang Wan + black cohosh tablet, 2 tablets, twice/day           Placebo, 2 tablets, twice/day                                                                                                                                                                                                          Frequency, severity and score of hot flushes, GCL \[total, psychological, anxiety, depression, somatic, vasomotor, sex\], HFRDI total Scale, AE

  **Xia et al. 2012 \[[@pone.0222383.ref034]\]**              Hospital of university                          72 (T: 36, C: 36)/64 (T: 32, C: 32)                                                                                                                                                              Perimenopausal: menstrual irregularity or amenorrhea for 3--11 months                                                                                                                        ≥ 14 hot flushes per week                                 8 weeks     modified Qing E Fang granule, 1 package (3.5g), once/day                                           Placebo, 1 package, once/day                                                                                                                                                                                                           MENQOL, hot flushes score (daily diary), frequency of night sweats, hormone (triglycerides (TG)), AE

  **Zhong et al. 2013 \[[@pone.0222383.ref035]\]**            Hospital                                        108/108 (T: 54, C: 54)                                                                                                                                                                           Irregular menstrual cycles ≥ 3 months or amenorrhea ≥ 3 months within the previous 12 months                                                                                                 Experiencing hot flushes, MRS ≥ 28                        12 weeks    Er Xian Tang granule, 15g a sachet, twice/day                                                      Placebo, a sachet, twice/day                                                                                                                                                                                                           MENQOL, frequency and severity of hot flushes and hot flush scores (daily diary), hormone (FSH, LH, E~2~, progesterone), blood pressure, AE

  **Zhou et al. 2007 \[[@pone.0222383.ref036]\]**             Hospital of university                          69/69 (T: 36, C: 33)                                                                                                                                                                             Ovariectomy and met the diagnostic criteria for menopausal symptoms (clinical and laboratory examination)                                                                                    Menopausal symptoms in the preceding 2 years              12 weeks    Geng Nian An granule, 1 sachet, twice/day                                                          Placebo, 1 sachet, twice/day                                                                                                                                                                                                           Modified KI scale, hormone (FSH, LH, E~2~), MI, AE
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AE, adverse events; C, control group; E~2~, estradiol; EoT, end of treatment; FSH, follicle-stimulating hormone; GCL, Greene climacteric scale; HFRDI, hot flash related daily interference; HRT, hormone replacement therapy; KI, Kupperman index; LH, luteinizing hormone; MENQOL, menopause-specific quality of life; MI, maturation index of vaginal exfoliative cells; MRS, Menopause Rating Scale; NS: not specified; PSQI, Pittsburgh sleep quality index; T, treatment group.

Methodological quality {#sec013}
----------------------

More than 50% included studies had low risks of bias in the domains of selection (random sequence generation), performance, attrition, reporting bias and other bias (baseline and funding). Seven studies did not specify the randomization method \[[@pone.0222383.ref019]--[@pone.0222383.ref023], [@pone.0222383.ref025], [@pone.0222383.ref035]\], and the rest provided appropriate randomization methods (e.g. Random number table method). Five studies provided adequate information on how to allocate randomization numbers to participants and achieved a low risk of bias on the allocation concealment \[[@pone.0222383.ref029], [@pone.0222383.ref031], [@pone.0222383.ref032], [@pone.0222383.ref034], [@pone.0222383.ref035]\]. Ten studies did not achieve blinding due to different forms of interventions used in two groups (e.g. decoction vs tablet, capsule vs tablet) \[[@pone.0222383.ref018]--[@pone.0222383.ref026], [@pone.0222383.ref028]\]. Six studies blinded outcome assessors \[[@pone.0222383.ref018], [@pone.0222383.ref029], [@pone.0222383.ref032]--[@pone.0222383.ref035]\]; the rest either used self-reported questionnaires or provided insufficient information on the blinding of outcome assessors. Potential attrition bias was noticed in six studies \[[@pone.0222383.ref023]--[@pone.0222383.ref025], [@pone.0222383.ref027], [@pone.0222383.ref030], [@pone.0222383.ref031]\]. Three articles reported protocol but failed to report findings for all the outcome measures described in the protocol \[[@pone.0222383.ref028], [@pone.0222383.ref032], [@pone.0222383.ref035]\]. The rest 16 articles did not publish protocols. The outcomes described in the results section matched those provided in the methods section in all 15 studies except one \[[@pone.0222383.ref019]\]. Five studies had imbalanced baseline data but did not address in data analyses \[[@pone.0222383.ref018], [@pone.0222383.ref021], [@pone.0222383.ref028], [@pone.0222383.ref030], [@pone.0222383.ref035]\]. Four studies investigated the herbal formulae supplied by drug manufacturers \[[@pone.0222383.ref029], [@pone.0222383.ref031]--[@pone.0222383.ref033]\]. Thus, these nine studies may be associated with other biases. The assessment of methodological quality is summarized and presented in Figs [2](#pone.0222383.g002){ref-type="fig"} and [3](#pone.0222383.g003){ref-type="fig"}.

![Risk of bias graph: Review authors\' judgements about each risk of bias item presented as percentages across all included studies.](pone.0222383.g002){#pone.0222383.g002}

![Risk of bias summary: Review authors\' judgements about each risk of bias item for each included study.](pone.0222383.g003){#pone.0222383.g003}

### Clinical effects {#sec014}

One study reported data from four arms: three treatment groups (Danzhiqing'e, Erzhi and combined formula) and one control group \[[@pone.0222383.ref026]\]. As a significantly imbalanced baseline of E~2~ between two treatment groups (Danzhiqing'e and Erzhi) and placebo was identified through baseline data analysis, data of these two comparisons were invalid and were excluded in the data analysis. Thus, only data from the treatment group of combined formula and the control group in this study were analyzed in this review.

### CHM versus HRT {#sec015}

Nine of the included articles compared CHM with HRT \[[@pone.0222383.ref018]--[@pone.0222383.ref026]\]. Seven of them reported subjective measures \[[@pone.0222383.ref018]--[@pone.0222383.ref022], [@pone.0222383.ref024], [@pone.0222383.ref026]\] and five reported objective measures including relevant hormone level and peripheral blood flow \[[@pone.0222383.ref018], [@pone.0222383.ref019], [@pone.0222383.ref021], [@pone.0222383.ref023], [@pone.0222383.ref025]\].

CHM showed no significant differences in the effectiveness rate of MHF compared to HRT (OR 0.73, 95% CI 0.16 to 3.46) \[[@pone.0222383.ref019]\], but the effects on the MHF score favored HRT group (MD 1.00, 95% CI 0.45 to 1.55) \[[@pone.0222383.ref024]\].

Two studies measured vasomotor symptoms. One study indicated that CHM had a similar effectiveness rate of vasomotor symptoms to HRT (OR 1.25, 95% CI 0.34 to 4.59) \[[@pone.0222383.ref022]\]. However, the other study demonstrated that the vasomotor domain of KI scores favored CHM (MD -0.43, 95% CI -0.55 to -0.31) \[[@pone.0222383.ref020]\].

Six studies reported the menopausal symptoms in the aspect of the total effectiveness rate, KI score and QoL \[[@pone.0222383.ref018]--[@pone.0222383.ref021], [@pone.0222383.ref024], [@pone.0222383.ref026]\]. The pooled data indicated CHM has no significantly different total effectiveness rate when compared to HRT (OR 1.41, 95% CI 0.84 to 2.35, I^2^ = 19%, [Fig 4](#pone.0222383.g004){ref-type="fig"}) \[[@pone.0222383.ref019]--[@pone.0222383.ref021], [@pone.0222383.ref026]\], total KI score (SMD -0.09, 95% CI -0.55 to 0.36, I^2^ = 84%, [Fig 5](#pone.0222383.g005){ref-type="fig"}) \[[@pone.0222383.ref018]--[@pone.0222383.ref020], [@pone.0222383.ref024], [@pone.0222383.ref026]\] and QoL (MD -1.05, 95% CI -5.24 to 3.14) \[[@pone.0222383.ref024]\]. However, the results of the number of menopausal symptoms favored HRT group (MD 1.74, 95% CI 0.17 to 3.31) \[[@pone.0222383.ref018]\].

![Meta-analysis of the total effectiveness rate of Chinese herbal medicine compared to menopausal hormone therapy for the treatment of menopausal hot flushes.](pone.0222383.g004){#pone.0222383.g004}

![Meta-analysis of the total KI score of Chinese herbal medicine compared to menopausal hormone therapy for the treatment of menopausal hot flushes.](pone.0222383.g005){#pone.0222383.g005}

Data analyses demonstrated that two studies had a significant imbalance at baseline, one study for the FSH and E~2~ \[[@pone.0222383.ref018]\], and the other are for the E~2~ and LH \[[@pone.0222383.ref021]\]. Therefore, the results of these outcome measures were not included in meta-analysis. After the invalid data were removed from these two studies, results indicated that CHM had similar effects to HRT on the FSH level (MD -0.91, 95% CI -5.25 to 3.42, I^2^ = 0%) \[[@pone.0222383.ref021], [@pone.0222383.ref023]\], but the results of the E~2~ level were higher in HRT group (MD -23.28, 95% CI -33.51 to -13.04, I^2^ = 0%) \[[@pone.0222383.ref019], [@pone.0222383.ref023]\]. One study revealed a significant reduction of blood flow in the jaw and fingertips in CHM group compared to HRT (MD -3.56, 95% CI -5.17 to -1.95 under the jaw, MD -7.10, 95% CI -10.99 to -3.21 in the fingertip) which indicated CHM had a stronger inhibition of peripheral blood flow in the upper body \[[@pone.0222383.ref025]\].

### CHM versus placebo {#sec016}

The other 10 RCTs compared CHM with placebo \[[@pone.0222383.ref027]--[@pone.0222383.ref036]\]. However, three of them were not included in the analysis due to lack of data \[[@pone.0222383.ref027], [@pone.0222383.ref029], [@pone.0222383.ref032]\]. All of the rest seven studies assessed subjective measures whereas only three of them evaluated objective measures including relevant hormone level \[[@pone.0222383.ref028], [@pone.0222383.ref035], [@pone.0222383.ref036]\].

Three different measures of MHF relief were used in the included studies, namely severity, frequency and score. Three studies reported MHF relief \[[@pone.0222383.ref030], [@pone.0222383.ref034], [@pone.0222383.ref035]\] and two reported changes of MHF relief \[[@pone.0222383.ref031], [@pone.0222383.ref033]\]. One study had significantly imbalanced MHF scores at the baseline so that it was not included in the analysis \[[@pone.0222383.ref035]\]. Data analysis results indicated a significant reduction of MHF severity in the CHM group compared to placebo group (MD -0.70, 95% CI-1.00 to -0.40) \[[@pone.0222383.ref035]\], but not significant in MHF frequency (SMD -0.06, 95% CI -0.26 to 0.15, I^2^ = 15%) \[[@pone.0222383.ref030], [@pone.0222383.ref035]\] or score (MD -0.64, 95% CI -2.17 to 0.89) \[[@pone.0222383.ref034]\]. Additionally, no significant differences of the changes in MHF relief were detected between CHM and placebo: frequency (SMD 0.02, 95% CI -0.35 to 0.40, I^2^ = 36%) \[[@pone.0222383.ref031], [@pone.0222383.ref033]\], severity (MD -0.49, 95% CI -1.41 to 0.43) \[[@pone.0222383.ref031]\], and score (MD 0.09, 95% CI -0.33 to 0.50) \[[@pone.0222383.ref033]\].

Six studies reported the score of vasomotor domains in the QoL questionnaire \[[@pone.0222383.ref028], [@pone.0222383.ref030], [@pone.0222383.ref033]--[@pone.0222383.ref036]\]. The synthesized data indicated CHM group showed no significant difference in the vasomotor score (SMD -0.91, 95% CI -1.90 to 0.07, I^2^ = 95%, [Fig 6](#pone.0222383.g006){ref-type="fig"}) \[[@pone.0222383.ref028], [@pone.0222383.ref034]--[@pone.0222383.ref036]\] or the changes of vasomotor scores (SMD 0.21, 95% CI -0.08 to 0.51) \[[@pone.0222383.ref030], [@pone.0222383.ref033]\] compared to that in placebo group at the end of treatment period.

![Meta-analysis of the vasomotor domain score of quality of life of Chinese herbal medicine compared to placebo for the treatment of menopausal hot flushes.](pone.0222383.g006){#pone.0222383.g006}

Included studies also assessed QoL \[[@pone.0222383.ref028], [@pone.0222383.ref035]\], changes of QoL \[[@pone.0222383.ref031], [@pone.0222383.ref033]\] and total KI score \[[@pone.0222383.ref036]\]. The findings indicated that CHM significantly improved the total KI score (MD -12.61, 95% CI -15.21 to -10.01) \[[@pone.0222383.ref036]\], but not in QoL (SMD -0.33, 95% CI -0.83 to 0.17, I^2^ = 77%) \[[@pone.0222383.ref028], [@pone.0222383.ref035]\] or changes of QoL (SMD 0.08, 95% CI -0.20 to 0.46, I^2^ = 0%) \[[@pone.0222383.ref031], [@pone.0222383.ref033]\].

Three studies measured the E~2~ and FSH levels at the end of treatment \[[@pone.0222383.ref028], [@pone.0222383.ref035], [@pone.0222383.ref036]\] and two of them also measured the LH level \[[@pone.0222383.ref035], [@pone.0222383.ref036]\]. There were no statistically significant differences in hormone levels between CHM and placebo groups ([Table 2](#pone.0222383.t002){ref-type="table"}).

10.1371/journal.pone.0222383.t002

###### Data analyses of hormone levels between Chinese herbal medicine and placebo groups at baseline and at the end of treatment.

![](pone.0222383.t002){#pone.0222383.t002g}

  Hormone                                        Intervention                                        CHM vs placebo at baseline (MD \[95% CI\])                      CHM vs placebo at the end of treatment (MD \[95% CI\])
  ---------------------------------------------- --------------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------------
  Estradiol (E~2~)                               Combined formula \[[@pone.0222383.ref028]\]         -15.88 \[-41.69, 9.93\]                                         73.32 \[44.30, 102.34\] [\*](#t002fn002){ref-type="table-fn"}
  Er Xian decoction \[[@pone.0222383.ref035]\]   -76.10 \[-177.12, 24.92\]                           16.30 \[-133.14, 165.74\]                                       
  Geng Nian An \[[@pone.0222383.ref036]\]        0.30 \[-2.59, 3.19\]                                11.40 \[7.82, 14.98\][\*](#t002fn002){ref-type="table-fn"}      
  Total                                                                                              37.92 \[-16.75, 92.59\], I^2^ = 88%                             
  Follicle-stimulating hormone (FSH)             Dan Zhi Qing E formula \[[@pone.0222383.ref028]\]   -2.06 \[-9.91, 5.79\]                                           1.16 \[-6.03, 8.35\]
  Er Zhi formula \[[@pone.0222383.ref028]\]      -1.58 \[-8.73, 5.57\]                               -1.06 \[-9.45, 7.33\]                                           
  Combined formula \[[@pone.0222383.ref028]\]    0.08 \[-7.62, 7.78\]                                1.60 \[-5.46, 8.66\]                                            
  Er Xian decoction \[[@pone.0222383.ref035]\]   13.80 \[-0.49, 28.09\]                              16.20 \[1.67, 30.73\]                                           
  Geng Nian An \[[@pone.0222383.ref036]\]        0.60 \[-4.95, 6.15\]                                -12.30 \[-17.46, -7.14\][\*](#t002fn002){ref-type="table-fn"}   
  Total                                                                                              0.32 \[-13.79, 14.43\], I^2^ = 89%                              
  Luteinizing hormone (LH)                       Er Xian decoction \[[@pone.0222383.ref035]\]        2.90 \[-3.06, 8.86\]                                            4.90 \[-0.67, 10.47\]
  Geng Nian An \[[@pone.0222383.ref036]\]        0.50 \[-2.81, 3.81\]                                -9.80 \[-13.16, -6.44\][\*](#t002fn002){ref-type="table-fn"}    
  Total                                                                                              -2.62 \[-17.03, 11.78\], I^2^ = 95%                             

Notes

\*, significant difference favored CHM group. Abbreviations: CHM, Chinese herbal medicine; CI, confidence intervals; MD, mean difference.

### Safety {#sec017}

Two out of the 19 included studies did not provide the safety data of interventions \[[@pone.0222383.ref019], [@pone.0222383.ref025]\]. Five studies indicated that no AEs were reported in the CHM group \[[@pone.0222383.ref018], [@pone.0222383.ref020], [@pone.0222383.ref021], [@pone.0222383.ref026], [@pone.0222383.ref036]\]. One study reported CHM had much fewer AEs than HRT \[[@pone.0222383.ref022]\]. Five trials stated that no statistically significant differences in AEs were observed between CHM and control groups \[[@pone.0222383.ref027], [@pone.0222383.ref030], [@pone.0222383.ref031], [@pone.0222383.ref033], [@pone.0222383.ref035]\]. The rest studies reported AEs from each arm without a statement of comparison between both arms. The most commonly seen AEs were gastrointestinal symptoms (such as loose stools, stomach discomfort/ache, nausea) (93/1010) and breast tenderness (31/229) ([S3 Table](#pone.0222383.s004){ref-type="supplementary-material"}).

### Sensitivity analyses and publication bias {#sec018}

Due to the limited number of included studies, sensitivity analysis could not be performed in this review.

Four RCTs compared CHM and HRT as well as nine studies compared CHM with placebo involved more than one study, thus their Rosenthal Failsafe-Ns were assessed for publication bias. Most outcomes presented a Failsafe-N at 0 including total effectiveness rate, total KI score, FSH level when comparing CHM with HRT; MHF frequency, changes in MHF frequency, changes of vasomotor scores, changes of QoL and FSH when comparing CHM with placebo. Other Failsafe-Ns are summarized in [Table 3](#pone.0222383.t003){ref-type="table"}.

10.1371/journal.pone.0222383.t003

###### Other Rosenthal Failsafe-N for publication bias in outcome measures included more than one studies.

![](pone.0222383.t003){#pone.0222383.t003g}

  Outcomes                  Comparisons          Studies                                                                      Rosenthal Failsafe-N
  ------------------------- -------------------- ---------------------------------------------------------------------------- ----------------------
  **Estradiol**             CHM versus HRT       \[[@pone.0222383.ref019], [@pone.0222383.ref023]\]                           7
  **Vasomotor score**       CHM versus placebo   \[[@pone.0222383.ref028], [@pone.0222383.ref034]--[@pone.0222383.ref036]\]   53
  **Quality of life**       CHM versus placebo   \[[@pone.0222383.ref028], [@pone.0222383.ref035]\]                           4
  **Estradiol**             CHM versus placebo   \[[@pone.0222383.ref035], [@pone.0222383.ref036]\]                           38
  **Luteinizing hormone**   CHM versus placebo   \[[@pone.0222383.ref035], [@pone.0222383.ref036]\]                           3

Abbreviation: CHM, Chinese herbal medicine.

### Frequency of CHM formulae and herbs {#sec019}

Among the included studies, 18 formulae were prescribed to the participants ([S2 Table](#pone.0222383.s003){ref-type="supplementary-material"}). Two formulae were investigated in more than one study, namely Kun Tai capsule \[[@pone.0222383.ref019], [@pone.0222383.ref023], [@pone.0222383.ref024]\] and Gui Zhi Fu Ling Wan \[[@pone.0222383.ref025], [@pone.0222383.ref032]\]. Other formulae were six classic CHM formulae \[[@pone.0222383.ref018], [@pone.0222383.ref021], [@pone.0222383.ref028], [@pone.0222383.ref030], [@pone.0222383.ref035]\], five newly developed formulae \[[@pone.0222383.ref020], [@pone.0222383.ref026], [@pone.0222383.ref029], [@pone.0222383.ref031], [@pone.0222383.ref036]\], four modified formulae \[[@pone.0222383.ref022], [@pone.0222383.ref027], [@pone.0222383.ref033], [@pone.0222383.ref034]\], and one combined formula \[[@pone.0222383.ref028]\]. The top 10 frequently ranked individual herbs in the included studies were Bai shao (Paeoniae Radix Alba, *Paeonia lactiflora* Pall.) (n = 12), Shu di huang (Rehmanniae Radix Praeparata, *Rehmannia glutinosa* Libosch.) (n = 9), Nü zhen zi (Ligustri Lucidi Fructus, *Ligustrum lucidum* Ait.) (n = 9), Fu ling (Poria, *Poria cocos* (Schw.) Wolf) (n = 8), Dang gui (Angelicae Sinensis Radix, *Angelica sinensis* (Oliv.) Diels) (n = 8), Zhi mu (Anemarrhenae Rhizoma, *Anemarrhena asphodeloides* Bge.) (n = 7), Chai hu (Bupleuri Radix, *Bupleurum chinense* DC. or *Bupleurum scorzonerifolium* Willd.) (n = 6), Mu dan pi (Moutan Cortex, *Paeonia suffruticosa* Andr.) (n = 6), Huang qin (Scutellariae Radix, *Scutellaria baicalensis* Georgi) (n = 5), Suan zao ren (Ziziphi Spinosae Semen, *Ziziphus jujuba* Mill. var. spinosa (Bunge) Hu ex H. F. Chou) (n = 5), and Yin yang huo (Epimedii Folium, *Epimedium brevicornum* Maxim., *Epimedium sagittatum* (Sieb. et Zucc.) Maxim., *Epimedium pubescens* Maxim. or *Epimedium koreanum* Nakai) (n = 5). The network of herb pairs in the prescribed CHM formulae from included studies is presented in [Fig 7](#pone.0222383.g007){ref-type="fig"}. The top three frequently used herb pairs in the prescribed formulae were Chai hu plus Bai shao, Bai shao plus Shu di huang, and Bai shao combined with Dang gui (n = 6). The following pairs were Chai hu plus Shu di huang, Chai hu plus Dang gui, Bai shao plus Nü zhen zi, and Dang gui plus Nü zhen zi (n = 5).

![The network of herb pairs in the prescribed CHM formulae from included studies.](pone.0222383.g007){#pone.0222383.g007}

Discussion {#sec020}
==========

MHF is one of the menopausal symptoms which occur before, during and after menopause transition \[[@pone.0222383.ref002]\]. CHM offers more options to MHF management in patients with concerns about HRT, but more evidence was warranted \[[@pone.0222383.ref008], [@pone.0222383.ref009]\]. This study aimed to evaluate the therapeutic effects and safety of CHM formulae.

More than half of included studies had low risks of bias in random sequence generation, blinding of participants and personnel, attrition, reporting and baseline comparison. After removing the studies with imbalanced baseline, the findings of this review suggested that CHM had similar effects to HRT in the effectiveness rate (MHF, vasomotor symptoms and menopausal symptoms), total KI score, QoL and FSH level. CHM could significantly improve the score of vasomotor domains of QoL and upper-body peripheral blood flow (jaw and fingertips) compared to HRT. CHM also significantly reduced the severity of MHF and total KI score compared to the placebo group, but with no significant difference in hormone levels. Although the majority of the studies measured MHF relief and QoL as the primary outcomes, different measures were used across studies, which led to difficulty in data synthesis. Most of the studies reported findings at the end of treatment, whilst a few reported the changes from baseline \[[@pone.0222383.ref030], [@pone.0222383.ref031], [@pone.0222383.ref033]\] which could not be synthesized with other results. Additionally, several different scales were utilized to measure QoL in the identified studies including Greene Climacteric Scale, Green Scale score, Hot Flash Related Daily Interference, Menopause-Specific Quality of Life and Menopause Rating Scale. Application of a standardized QoL questionnaire may make the data synthesis and comparison across studies more feasible.

Positive clinical effects of CHM may be related to potential estrogen-like actions of the prescribed herbs. In the identified popularly prescribed herbs, Bai shao, Dang gui, Zhi mu, Chai hu, Huang qin and Yin yang huo have been found to contain phytoestrogens by gas chromatography-mass spectrometry \[[@pone.0222383.ref037]\]. Shu di huang, Bai shao and Dang gui were examined to have phytoestrogenic effects on Sprague Dawley rats and cultural MCF-7 cells \[[@pone.0222383.ref038]\]. Yin yang huo showed bidirectional adjustment of estrogenic effects (when inverted independently or together with diethylstilbestrol) in female Kunming mice. The direction of phytoestrogenic effects depended on the internal estrogen level \[[@pone.0222383.ref039]\]. The combination of Nü zhen zi and Han lian cao (Ecliptae Herba, *Eclipta prostrata* L.) demonstrated an effect in activating the estrogenic activity in an *in vitro* study using cultural MCF-7 cells line \[[@pone.0222383.ref040]\].

Another hypothesized specific vasodilator of MHF in humans, named CGRP, is responsible for peripheral circulation by affecting the signal transition of the perivascular nerves \[[@pone.0222383.ref041]\]. It significantly rises during MHF episodes \[[@pone.0222383.ref006]\]. Three of the top ten popular prescribed herbs, namely Bai shao, Mu dan pi and Fu ling, also ingredients of Gui Zhi Fu Ling Wan, were found to significantly reduce the plasma concentration of CGRP \[[@pone.0222383.ref042]\].

To the best of our knowledge, there is no published study which has reviewed CHM for MHF. Three studies reviewed CHM on menopausal symptoms in 2008, 2010 and 2012 \[[@pone.0222383.ref043]--[@pone.0222383.ref045]\] and one study reviewed CHM on drug-induced hot flushes in breast cancer patients \[[@pone.0222383.ref046]\]. The current review differs from them as it focused on patients with MHF and compared CHM with HRT or placebo only. Thus, a different set of RCTs from other reviews was included in our review. However, this review did not search databases in other languages, such as Japanese or Korean. Thus, there is a possibility that some studies related to CHM for MHF have not been identified.

CHM appears to be safe for females with MHF as AEs were few and mild. Overall, there is no noteworthy risk of intakes of CHM. As some herbs may have phytoestrogenic effects or estrogen-like effects, they should be used with caution when prescribed to patients with hormone-dependent conditions, such as breast cancer \[[@pone.0222383.ref046]\]. Further investigations of contraindications and possible herb-drug interactions are needed \[[@pone.0222383.ref028], [@pone.0222383.ref046]\].

Conclusions {#sec021}
===========

Noting the limitation of quality and quantity of the results, it is worth further exploring CHM as an alternative therapy to improve the MHF sufferers' subjective feeling as well as the objective changes in peripheral blood flow. Due to the high variations of investigated CHM formulae in the included studies, future rigorously conducted studies investigating on a specific non-modified CHM formula for the management of MHF are recommended.
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